- What: The Global Advisory Board and the National Steering Committee in Kenya provide advice and analyse learnings from the Healthy Heart Africa programme.
- Scope: The Board and Committee support the Healthy Heart Africa programme, which targets hypertension in Africa (initially in Kenya).
- Objective: Through the Board and the Committee, AstraZeneca seeks to improve the programme and develop new learnings to take forward in reaching more patients.
- Details: The Board consists of international experts in global health; the Committee consists of local stakeholders for the roll-out of the programme in Kenya.
The Healthy Heart Africa programme targets hypertension in Africa (initially in Kenya). As part of the Healthy Heart Africa programme, AstraZeneca has developed an internal governance structure consisting of different stakeholders. The stakeholder engagement process has consisted of interactions with the Kenyan government, both nationally and locally, local non-government organisations, medical societies, and global health organisations.
Through a Global Advisory Board, which consists of multiple leaders in global health, AstraZeneca seeks to improve the programme and develop new learnings to take forward in reaching more patients. Locally, the programme has convened a National Steering Committee which is led by the Kenyan Government and involves both national and county representatives. This has been an important platform to share learnings and data and ensure that AstraZeneca continues to support government priorities. The aim of all these relationships, which AstraZeneca previously did not have, is to create a sustainable programme to innovate in providing access to hypertension care for patients, including the provision of affordable medicines.
Creating platforms for dialogue through steering committees and the company global advisory board, has led to increased learnings for the programme in how to best address hypertension, and other non-communicable diseases, in healthcare systems which are designed to address communicable diseases. The programme has significant cross-functional organisation and on-the-ground resources, along with a large core team based in many different locations around the world – in Kenya, South Africa, Dubai and London.